|Bid||90.51 x 900|
|Ask||97.50 x 1100|
|Day's range||91.51 - 95.91|
|52-week range||32.97 - 138.52|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||08 Nov 2021 - 12 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||127.13|
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.
After the Food and Drug Administration paused Allogene Therapeutics' (NASDAQ: ALLO) clinical trials last week, the stock was crushed. The FDA's intervention appeared to spur trading by ARK Invest in Beam Therapeutics (NASDAQ: BEAM), Intellia Therapeutics (NASDAQ: NTLA), and Schrödinger (NASDAQ: SDGR).
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics